BEBT-109
Product Specifications
UNSPSC Description
BEBT-109 is a potent pan-mutant-selective EGFR inhibitor. BEBT-109 has improved pharmacokinetic properties. BEBT-109 can be used for multiple mutant-EGFR-driven non-small cell lung cancer (NSCLC) research[1].
Target Antigen
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bebt-109.html
Solubility
10 mM in DMSO
Smiles
C=CC(NC1=CC(NC2=NC=CC(N3C=CC4=NC(OC)=CC=C43)=N2)=C(OC)C=C1N(CCN(C)C)C)=O
Molecular Weight
516.59
References & Citations
[1]Fan F, et al BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer. Transl Oncol. 2021 Feb;14(2):100961.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-W423595/BEBT-109-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-W423595/
Clinical Information
Phase 2
CAS Number
2050906-40-4
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1010452-01 0.02 mg (E-Coli)
Recombinant Escherichia coli 2,3-diketo-L-gulonate reductase (dlgD)
Ask
View Details MBS1010452-02 0.02 mg (Yeast)
Recombinant Escherichia coli 2,3-diketo-L-gulonate reductase (dlgD)
Ask
View Details MBS1010452-03 0.1 mg (E-Coli)
Recombinant Escherichia coli 2,3-diketo-L-gulonate reductase (dlgD)
Ask
View Details MBS1010452-04 0.1 mg (Yeast)
Recombinant Escherichia coli 2,3-diketo-L-gulonate reductase (dlgD)
Ask
View Details MBS1010452-05 0.02 mg (Baculovirus)
Recombinant Escherichia coli 2,3-diketo-L-gulonate reductase (dlgD)
Ask
View Details